P3.02b-075 Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients Tao Jiang, Shengxiang.

Slides:

Advertisements

Similar presentations

High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules Chunyan Wu, MD, Chao Zhao, MD, Yang Yang,

Advertisements

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

SC17.02 Lung Cancer in China: Challenges and Perspectives

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation Alessandro Russo, MD, Tindara.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

P3.02b-001 Phase 1 Dose Escalation of PF (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R+/-T790M) NSCLC Hatim Husain,

SC09.04 Radiotherapy in China

Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer Xiaoxia Chen,

P3.02b-029 Primary Double EGFR Mutations T790M and Mutation in Exon 19 or 21 - Prevalence and Treatment Results in Slovakian NSCLC Patients Peter Berzinec,

P3.02b-016 An Exploration Study of Mechanisms Underlying Primary Resistance to EGFR-TKIs in Patients Harboring TKI-Sensitive EGFR Mutations Ee Ke, Zhihong.

NA Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

P Transcriptional Profiling Identified the Anti-Proliferative Effect of Mitofusin-2 Deficiency and Its Risk in Lung Adenocarcinoma Yuqing Lou,

Clinical Outcome of ALK-Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors.

P Typical Morphological Features Revealed Unfavorable Survival Benefits in High-Grade Neuroendocrine Carcinomas Hao-Ran Zhai, Jia-Tao Zhang,

PUB023 Effectiveness of Three-Dimensional Video System in Single Port Thorascopic Major Pulmonary Resection: Propensity Score Matched Analysis Hyun Koo.

P Risk Stratification Model to Predict Survival Following Surgical Resection for Lung Cancer Using Pathological Variables Timothy Edwards, Charlene.

P Pleural CEA and C-Reactive Protein in Patients with Lung Metastases and Malignant Pleural Effusion. A Prospective Case-Control Study Franco.

EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases Tao.

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

P Molecular Characterization of Non-Small Cell Lung Cancers (NSCLC) in Young Patients from an Argentine Population V. Denninghoff, G. Recondo,

P SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (NSCLC). A UK Randomized Phase III Trial Yenting Ngai,

P3.02b-125 Failure to Tyrosine Kinase Inhibitors and Patterns of Progression in Patients with Advanced Non-Small Cell Lung Cancer Feliciano Barron, Laura-Alejandra.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes Yayi He, MD, PhD, Hui.

P3.02a-012 Patient-Reported Symptoms and Quality of Life (QoL) in East Asian Patients with ALK+ NSCLC Treated with Crizotinib vs Chemotherapy You Lu,

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

P3.02b-062 Safety of Necitumumab and Abemaciclib Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Benjamin Besse, Johan.

P Predictors of Survival after Whole Brain Radiotherapy for Patients with Brain Metastasized Lung Cancer Georgios Tsakonas, Fatou Hellman, Signe.

Support Your Specialty

PUB010 Intraoperative Blood Loss is an Independent Predictor of Poor Disease Free Survival for Patients Undergoing VATS Lobectomy for Lung Cancer M.

ED11.01 Systemic Therapy for Advanced Oncogene-Driven NSCLC

P3.02b-061 A Phase II Study of Nab-Paclitaxel (Nab-P) in Patients with Advanced Non- Small Cell Lung Cancer (NSCLC) with EGFR Mutations Christina Baik,

JCSE01.16 Positive Correlation Between Whole Genomic Copy Number Variant Scoring and the Grading System in Lung Non-Mucinous Invasive Adenocarcinoma

ES Lung Cancer Surgery for High Risk Patients

P Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Nicola.

MTP13-01: Indications and limitations of bronchoscopy

Table of contents The Journal for Nurse Practitioners

Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients with NSCLC and M1a Disease? Chenyang Dai, MD, Yijiu Ren, MD, Dong Xie, MD, PhD,

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

P3.02b-017 Sequence of EGFR-TKI Therapy and BIM Deletion Polymorphism Affect the Outcome of Treatment in EGFR Positive NSCLC Chanchai Charonpongsuntorn,

P3.02b-052 Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG S1403 Sarah Goldberg, James.

P3.02a-023 Treatment Patterns and Early Outcomes of ALK+ Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study Edmond Bendaly,

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

M. Kusumoto Journal of Thoracic Oncology

In This Issue Journal of Thoracic Oncology

Table of Contents Journal of Thoracic Oncology

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

International Thymic Malignancies Interest Group: A Way Forward

P Impact of Systematic EBUS-TBNA Mediastinal Staging on Radical Radiotherapy Planning in NSCLC N. Hardcastle, A. Cole, G. Turgeon, R. Thomas,

European Lung Cancer Conference (ELCC) 2016 Organisation

OA Video-Assisted Thoracoscopic Surgery vs

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping Wei Jin, MD, Benjie Shan, MD, Hu Liu, PhD, Shoubing Zhou, PhD, Wenjuan.

PUB001 Advanced NSCLC Patients at the Extremes of Age in the Era of EGFR-TKIs Yu-Mu Chen, Chien-Hao Lai, Huang-Chih Chang, Tung-Ying Chao, Chia-Cheng.

P Combined Molecular and Radiological Evaluation Unveils Three Subtypes of Disease Progression to a Third Generation EGFR TKI Y. Zhang, Q. Zhou,

P2.03b-002 Efficacy and Safety of WBRT Combined with Endostar in Patients with Advanced Non-Small Cell Lung Cancer Xiaorong Dong, Ruiguang Zhang, Xican.

PS01.07 The Clinical Necessity of Extended Thymectomy for Thymic Squamous Cell Carcinomas Revealed by Exome Sequencing J. Jiang, Y. Zhang, C. Jin, J.

Discussion The Journal of Thoracic and Cardiovascular Surgery

IASLC 6th Latin American Conference on Lung Cancer

P Clinical Consequences, Quality of Life, and Management of Neutropenic NSCLC Patients in the REVEL Trial D. Ettinger, O. Arrieta, N. Karaseva,

PUB006 Impact of the New WHO Classification of Thymic Tumors: Cross-Validation of the Prognostic Value in a Single Institution Cohort Mohamed Kamel,

P New Clinical T Classification Is Associated with Pathological Stage I Invasive Adenocarcinoma with Solid Histologic Subtype Y. Sawai, J. Nitadori,

OA Survival Trends Among Non-Small Cell Lung Cancer (NSCLC) Patients Over A Decade: Impact of Initial Therapy at Academic Centers B. Dholaria,

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

M. Pasquinelli, Z. Deliu, D. Rosenberg, C. Weldon, S. Obilade, A

Y. Lou, R. Manochakian, J. Cochuyt, D. Hodge, S. Ailawadhi

Robert Comis, MD, The Passing of a “Lung Man”

ED04.01 Surgery in Bronchopulmonary Typical and Atypical Carcinoids

Presentation transcript:

P3.02b-075 Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients Tao Jiang, Shengxiang Ren, Caicun Zhou Journal of Thoracic Oncology Volume 12, Issue 1, Pages S1235-S1236 (January 2017) DOI: 10.1016/j.jtho.2016.11.1742 Copyright © 2016 Terms and Conditions

Journal of Thoracic Oncology 2017 12, S1235-S1236DOI: (10.1016/j.jtho.2016.11.1742) Copyright © 2016 Terms and Conditions

Journal of Thoracic Oncology 2017 12, S1235-S1236DOI: (10.1016/j.jtho.2016.11.1742) Copyright © 2016 Terms and Conditions